Title of each class Trading Symbol(s) Name of each exchange on which registered Table of Contents Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 7 PART II - OTHER INFORMATION Item 4. Mine Safety Disclosures 38 PART I – FINANCIAL INFORMATION The accompanying notes are an integral part of these condensed consolidated financial statements. 3 | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------- ...

Repligen Corporation [RGEN] Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Tony Hunt - CEO Jason Garland - CFO Olivier Loeillot - President & CCO Sondra Newman - IR Conference Call Participants Rachel Vatnsdal - J.P. Morgan Dan Arias - Stifel Jacob Johnson - Stephens Inc. Puneet Souda - Leerink Partners Justin Bowers - Deutsche Bank Matt Larew - William Blair Conor McNamara - RBC Capital Markets Dan Leonard - UBS Paul Knight - KeyBanc Matt Hewitt - Craig-Hallum Capital Group ...

Repligen (RGEN) came out with quarterly earnings of $0.33 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this drug developer would post earnings of $0.29 per share when it actually produced earnings of $0.28, delivering a surprise of -3.45%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Repligen, which belongs to t ...

Reported revenue was $154 million compared to $159 million, bringing our first half of 2024 revenue to $305 million, in line with our expectations. areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www. ...

Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applications Accelerates expansion into new modality markets with a unique, scalable purification solution Strongly synergistic with AVIPure® affinity ligands and OPUS® pre-packed chromatography columns Tantti's DuloCore® technology platform combines the high throughput performance of membranes with the rapid mass transfer of monoliths in a convenient and flexible bead format. Combined with AVIPure affi ...

About Repligen Corporation This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and unce ...

WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2024. Repligen Corporation is a global life sciences company that develops and commercial ...

Repligen (RGEN) shares ended the last trading session 4.4% higher at $125.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 24.4% loss over the past four weeks. Earlier this month, the company announced that it has promoted Olivier Loeillot, its current chief commercial officer (CCO), as its new president and chief executive officer (CEO), effective from Sep 1, 2024. This might have driven the share price rally. ...

Repligen Corporation (RGEN) announced that it has promoted Olivier Loeillot, its current chief commercial officer (CCO), as its new president and chief executive officer (CEO), effective from Sep 1, 2024. The company's current CEO, Tony J. Hunt, will step down from his role and will transition to executive chair with effect from Sep 1, 2024. Shares of RGEN fell 11.9% on Jun 13 following the announcement of the news. Olivier Loeillot joined Repligen as president and CCO in October last year. Prior to joining ...

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. L ...